| Cat. No. |
Product Name |
Information |
| PC-21699 |
Tipranavir
HIV-1 protease inhibitor
|
Tipranavir (PNU-140690) is a potent, nonpeptidic and orally bioavailable HIV protease inhibitor with Ki vaule of 8 pM, shows an IC90 value of 100 nM in antiviral cell culture. |
| PC-20513 |
BDM2
IN-LEDGF/p75 inhibitor
|
BDM2 is a potent, HIV-1 Integrase IN-LEDGF allosteric inhibitor (INLAI), shows potent anti-HIV activity. |
| PC-38800 |
JX-7
NNRTI
|
JX-7 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with remarkable inhibitory activity against wild-type HIV-1 (EC50=5 nM) and numerous clinically observed variants in MT-4 cells. |
| PC-38744 |
Emivirine
HIV-1 RT inhibitor
|
Emivirine (MKC-442) is a highly potent and selective inhibitor of HIV-1 reverse transcriptase (RT) with IC50 of 8 nM, does not inhibit HIV-1 RNase H, other RTs, or DNA polymerase alpha. |
| PC-38643 |
GSK3839919
HIV-1 integrase inhibitor
|
GSK3839919 is a potent, allosteric HIV-1 integrase inhibitor (ALLINI). |
| PC-38594 |
BRD-K98645985
BAF inhibitor
|
BRD-K98645985 is a small molecule inhibitor of BAF (mammalian SWI/SNF)-mediated transcription with EC5 of 2.37 uM, binds ARID1A-specific BAF complexes, reverses HIV-1 latency in vitro and ex vivo. |
| PC-38556 |
Q308
Latent HIV-1 inhibitor
|
Q308 is a small molecule that silences the latent HIV-1 provirus by inhibiting Tat-mediated gene transcription and selectively downregulates the expression levels of the facilitated chromatin transcription (FACT) complex. |
| PC-38494 |
SRI-41897
HIV-1 Vpu inhibitor
|
SRI-41897 is a specific small molecule inhibitor of HIV-1 N-terminal region of NL4-3 Vpu (HIV-1 NL4-3 Vpu) with EC50 of 4.4 uM in the GaLV inhibition assays. |
| PC-38387 |
Elunonavir
HIV inhibitor
|
Elunonavir is an azapeptide atazanavir analogs useful for treating HIV infections. |
| PC-73246 |
NBD-14273
HIV entry inhibitor
|
NBD-14273 is a CD4-mimetic, small-molecule HIV-1 entry inhibitor with IC50 of 0.13 uM. |
| PC-72432 |
SBI-0637142
Latency-reversing agent
|
SBI-0637142 is a potent Smac mimetic that preferentially targets BIRC2, latency-reversing agent (LRA), specifically and potently promote HIV-1 latency reversal activity. |
| PC-72431 |
Ciapavir
Latency-reversing agent
|
Ciapavir (SBI-0953294, cIAP1 antagonist for viral reactivation) is a bivalent, next-generation, Smac mimetic and antagonist of cIAP1 as latency-reversing agent (LRA), specifically and potently promote HIV-1 latency reversal activity both in vivo. |
